Boudicca Dx and Adial Partner to Advance Precision Medicine for Alcohol Use Disorder

Boudicca Dx, LLC, a worldwide precision medicine testing accelerator, has announced a partnership with Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focussing on developing treatments for the treatment and prevention of addiction and associated illnesses.

As part of Adial's regulatory strategy for its lead investigational asset, AD04, a genetically targeted, serotonin-3 receptor antagonist therapeutic agent for the treatment of alcohol use disorder (AUD), Boudicca will assist Adial in advancing its technical and regulatory strategy for the Company's companion diagnostic genetic test. This will ensure that the test is validated both technically and clinically in accordance with FDA guidelines. The purpose of Adial's companion diagnostic is to assist AD04 in locating possible patients, including the enrolment of individuals for the Company's upcoming Phase 3 study.

"As we continue to prepare for the Phase 3 study for AD04, this agreement with Boudicca Dx is another key component towards achieving clinical success and is expected to support our next FDA interaction," stated Cary Claiborne, President and Chief Executive Officer of Adial. Adial's perfect partners in creating a thorough clinical, regulatory, and commercial plan for the AD04 companion diagnostic are Kelly Gordon, the CEO and creator of Boudicca Dx, and her group. Getting our companion diagnostic approved by the FDA is a crucial first step in our aim to treat AUD with a first-class precision therapy.

The Boudicca Dx team is thrilled to assist the creation of a first-in-class companion diagnostic test for AD04, a precision medication intended to treat patients with alcohol use disorder, according to Kelly Gordon. Over 30 million individuals in the US alone are afflicted by this illness, which results in 3 million fatalities annually on a global scale. The demand for a focused treatment and related diagnostic test is quite strong.